In less than a month, the executives of 13 pharmaceutical companies have changed!

In the context of the changing environment of the pharmaceutical industry, the executives of pharmaceutical companies have changed frequently
.
According to incomplete statistics, more than 300 senior executives of pharmaceutical companies have changed in 2021, and in 2022, from the beginning of January to January 25, at least 13 senior executives of pharmaceutical companies have changed, and many of the changed positions are directors President, Vice President, Deputy General Manager,
etc.
Xingqi Eye Medicine: Director resigns Recently, Xingqi Eye Medicine announced that the company's board of directors received a written resignation report from the company's director Mr.
Liu Gaozhi on January 21, 2022.
Mr.
Liu Gaozhi applied to the company's board of directors to resign as a director for personal reasons.
job title
.
After his resignation, Mr.
Liu Gaozhi no longer holds any position in the company
.
Hetian Weiyao: Director resigns On January 19, Hetian Weiyao announced that the board of directors of the company received the resignation report submitted by director Mr.
Pang Kejian on January 17, 2022, and the resignation will take effect on February 7, 2022
.
The above-mentioned resigners hold 0 shares of the company, accounting for 0% of the company's share capital
.
Not the target of joint punishment for dishonesty, and will no longer hold other positions in the company after resignation
.
ST Wanyao: Chief Financial Officer Resigned On January 18, ST Wanyao issued an announcement saying that the board of directors of the company received the resignation report submitted by the financial controller Li Jie on January 18, 2022, and will resign from January 18, 2022 effective
.
Li Jie will no longer hold other positions in the company after his resignation
.
It is reported that Li Jie resigned due to personal reasons
.
Dong E E Jiao: Chairman and President Resign On January 10, Dong E E Jiao Co.
, Ltd.
announced that the board of directors recently received a written resignation report submitted by Chairman Han Yuewei
.
According to the announcement, Han Yuewei resigned due to changes in job content
.
On the same day, Dong'e Ejiao also issued an announcement on the resignation of the president.
The board of directors of the company recently received a written resignation report submitted by Gao Dengfeng.
Due to the change in the work content, Gao Dengfeng applied for his resignation as the company's president and legal representative
.
After resigning, Gao Dengfeng continued to serve as a director of the tenth board of directors of the company, and was also elected as the chairman of the tenth board of directors of the company.

.
Former Takeda China executive joins Xinruinuo Pharmaceutical On January 7, Xinruinuo Pharmaceutical announced the appointment of Huang Haoyu as CEO and announced that the company was officially put into operation
.
According to the data, before joining Xinruinuo, Huang Haoyu served as the head of the oncology business unit of Takeda China, and successively served as the general manager of the Baxter nephrology business unit, the general manager of AbbVie Taiwan, and the deputy of the oncology business unit of Roche China.
President, General Manager of IMS Health Taiwan and Head of Novartis' Solid Tumor Business Unit
.
He has over 25 years of experience in the pharmaceutical industry
.
Shengxiang Bio: Deputy General Manager Resigns On January 6, Shengxiang Bio announced that the board of directors recently received a written resignation report from the company's deputy general manager Gui Yaokui, who applied for his resignation as the company's deputy general manager for personal reasons.
, and will no longer hold any position in the company after resignation
.
Buchang Pharmaceutical: Vice President Resigns On January 6, Buchang Pharmaceutical announced that the company's board of directors received a written resignation report submitted by the company's vice president Liu Luxiang on January 6, 2022.
Liu Luxiang applied for his resignation as the company's vice president due to personal reasons.
After resigning, he will not hold any position in the company
.
Sinopharm Co.
, Ltd.
: Deputy General Manager resigns On January 6, Sinopharm Co.
, Ltd.
announced that Zhu Lin would no longer serve as the secretary of the company's board of directors and the company's deputy general manager due to personal reasons
.
Former AstraZeneca executives joined Luoxin PharmaceuticalsOn January 5, Luoxin Pharmaceuticals reported that from January 4, 2022, Wang Dong joined Luoxin Health Technology Development (Beijing) Co.
, Ltd.
as the Chief Executive Officer of Luoxin Health Executive Officer (CEO), responsible for the strategic planning and management of Luoxin Health, and reporting directly to the board of directors of Luoxin Health.
At the same time, he is also the senior vice president of Luoxin Pharmaceutical's direct business business, and is fully responsible for the management of Luoxin Pharmaceutical's direct business.
, reported to Dong Lijun, COO of Luoxin Pharmaceutical
.
It is understood that Wang Dong is a former AstraZeneca executive and has many years of management experience in the retail business field.
In addition to serving as the head of the retail business department in AstraZeneca China, he was also responsible for the retail business of Xi'an Janssen
.
Sunflower Pharmaceuticals: New Board Secretary Appointed Sunflower Pharmaceuticals announced on the evening of January 5 that the company has decided to appoint Zhou Guangguang as the company's board secretary, and the term will expire until the current board of directors expires.

.
Bloomage Bio: Resignation of Deputy General Manager Bloomage Bio announced on the evening of January 4 that the board of directors recently received a written resignation report from Li Huiliang, the company's deputy general manager, chief technology officer and core technician, who resigned as the company's deputy general manager for personal reasons.
The positions of general manager and chief technical officer are no longer core technical personnel.
After resignation, they will no longer hold any positions in the company and subsidiaries
.
Huahai Pharmaceutical: Vice President Resigns On January 3, Huahai Pharmaceutical issued an announcement saying that the board of directors recently received the resignation document from the company's vice president Wang Jie.
Resignation will not affect the normal operation of the company
.
Gan & Lee Pharmaceuticals: Big Change of Executives On January 3, Gan & Lee Pharmaceuticals officially announced the appointment of Dr.
Mike Hu as the CEO and General Manager of Gan & Lee America to lead and be responsible for Gan & Lee's global clinical development and the management of its U.
S.
subsidiaries
.
According to information released by Gan & Lee Pharmaceuticals, Dr.
Mike Hu has more than 20 years of industry experience in preclinical research, clinical development and approval of innovative therapeutic drugs for oncology, hematology, endocrinology, metabolism, anti-infection, and rare diseases
.